CLINICAL TRIALS PROFILE FOR CORT118335
✉ Email this page to a colleague
Clinical Trials for CORT118335
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT03315338 ↗ | First-in-human Study in Healthy Subjects | Completed | Corcept Therapeutics | Phase 1 | This initial Phase I study will evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending doses of CORT118335, the effect of concomitant administration with food on exposure to CORT118335, and its pharmacological effect in healthy subjects. |
NCT03818256 ↗ | This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications. | Recruiting | Corcept Therapeutics | Phase 2 | This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant in obese adult with schizophrenia treated with antipsychotic medications. |
NCT03823703 ↗ | Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) | Terminated | Corcept Therapeutics | Phase 2 | This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis (NASH). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for CORT118335
Condition Name
Clinical Trial Locations for CORT118335
Trials by Country
Clinical Trial Progress for CORT118335
Clinical Trial Phase
Clinical Trial Sponsors for CORT118335
Sponsor Name